Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penehyclidine vs atropine for prevention of postoperative nausea and vomiting after thyroidectomy
ChiCTR2100050278Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of penehyclidine in postoperative nausea and vomiting (PONV) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Incidence of postoperative nausea and vomiting and other adverse events, Operation completion condition and 7 more. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
penehyclidine
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on ChiCTR2100050278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050278.